FOR HEALTHCAREPROFESSIONALS
Watch the TV spot that may have patients asking about XIFAXAN.
*Patients who experience recurrence can be retreated up to 2 times.1
†Median of 10 weeks (range of 6 to 24 weeks).1
‡Click here to see TARGET 3 Study Design.
Based on aggregated total of all prescribers as of October 2019.
IBS-D = irritable bowel syndrome with diarrhea
Get information regarding XIFAXAN
Speak with a XIFAXAN representative
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Thank you for visiting the XIFAXAN Professional website. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).
The information contained in this section of the site is intended for US healthcare professionals only.